Walsh Z
University of British Columbia-Okanagan, Kelowna, BC, Canada.
PreprintPsilocybin
Curious about Psilocybin? Prevalence and correlates of interest among adults with chronic pain.
ArticleMDMA
Retraction Note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
ArticleKetamine
Patients' Experiences Discussing Psychedelics for Therapeutic Purposes with Physicians and Other Health Care Providers.
ArticleKetamine
"This is you teaching you:" Exploring providers' perspectives on experiential learning and enhancing patient safety and outcomes in ketamine-assisted therapy.
ArticlePsilocybin
Therapeutic Potential of Psilocybin for Treating Psychological Distress among Survivors of Adverse Childhood Experiences: Evidence on Acceptability and Potential Efficacy of Psilocybin Use.
ArticleKetamine
Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: a retrospective chart review.
ArticlePsilocybin
Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls.
ArticleKetamine
Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review.
ArticlePsilocybin
Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers.
ArticlePsilocybin
Psychedelic-Assisted Psychotherapy After COVID-19: The Therapeutic Uses of Psilocybin and MDMA for Pandemic-Related Mental Health Problems.
ArticlePsychedelics
The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women.
ArticlePsilocybin
Psychedelic use and intimate partner violence: The role of emotion regulation.
ArticlePsilocybin